

Product Name: CB-5083 Revision Date: 06/05/2023

## **Product Data Sheet**

## **CB-5083**

Cat. No.: B6032

CAS No.: 1542705-92-9
Formula: C24H23N5O2


**M.Wt:** 413.47

Synonyms:

Target: Ubiquitination/ Proteasome

Pathway: p97

Storage: Store at -20°C



# Solvent & Solubility

insoluble in H2O; ≥20.65 mg/mL in DMSO; ≥4.4 mg/mL in EtOH

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	2.4186 mL	12.0928 mL	24.1856 mL
	5 mM	0.4837 mL	2.4186 mL	4.8371 mL
	10 mM	0.2419 mL	1.2093 mL	2.4186 mL

Please refer to the solubility information to select the appropriate solvent.

# **Biological Activity**

Shortsummary	p97 inhibitor			
IC <sub>50</sub> & Target				
In Vitro	Cell Viability Assay	The state of the s		
	Cell Line; poor constraints	HEK293T stably expressing TCRα-GFP, A549 and HCT116 cell lines		
	Preparation method:	The solubility of this compound in DMSO is >20.7mg/mL. General tips for		
		obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes		
		and/or shake it in the ultrasonic bath for a while. Stock solution can be stored		
		below -20°C for several months.		
	Reacting conditions:	2.5 μM, 6 hr;		

	Applications:	In human embryonic kidney 293T cells stably expressing TCRα-GFP, CB-5083
		treatment led to a dose-dependent accumulation of TCRα-GFP in the ER with
		EC50 of 0.73 $\pm$ 0.04 $\mu M.$ In the lung carcinoma cell line A549, CB-5083 led to
		accumulation of poly-ubiquitinated proteins. In HCT116 cells, CB-5083
	al <sup>o</sup> m	treatment resulted in accumulation of K48-ubiquitinated proteins at a higher
	Expose the June	molecular weight.
	Animal experiment	A CONTRACTOR OF THE CONTRACTOR
In Vivo	Animal models:	Nude or SCID-Beige mice xenografted with HCT116 derived from colorectal
		adenocarcinoma, NCI-H1838 derived from non-small-cell lung cancer, AMO-1
		derived from a plasmacytoma, and colorectal cancer patient-derived xenograft
		(PDX) models
	Dosage form:	oral administration, 25 and 100 mg/kg, 6 hr. oral gavage once (qd) or twice (bid)
		daily or following a 4 days on, 3 days off (qd4/3off) cycle.
	Applications:	CB-5083 (oral, 25 and 100 mg/kg) induced the UPR and apoptosis. Oral
	Theory	treatment with CB-5083 inhibited the growth of human tumor xenografts in
	50 Expose the	mice.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may
		slightly differ with the theoretical value. This is caused by an experimental
		system error and it is normal.

## **Product Citations**

See more customer validations on www.apexbt.com.

### References

[1]. Anderson D J, Le Moigne R, Djakovic S, et al. Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis[J]. Cancer Cell, 2015, 28(5): 653-665.

APENTAL BIO

#### Caution

#### FOR RESEARCH PURPOSES ONLY.

#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

2 | www.apexbt.com



## **APExBIO Technology**

#### www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



AREL ED TO THE STATE OF THE STA

A P. Landon B. Landon Cordan the Information

ARE Land to the Land of the La

ARE LEGION BOOM

Reduce Cartesian Explore the University